Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Y-box protein-1/p18 fragment identifies malignancies in patients with chronic liver disease

Authors: Frank Tacke, Nicolas Kanig, Abdelaziz En-Nia, Thilo Kaehne, Christiane S Eberhardt, Victoria Shpacovitch, Christian Trautwein, Peter R Mertens

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Immunohistochemical detection of cold shock proteins is predictive for deleterious outcome in various malignant diseases. We recently described active secretion of a family member, denoted Y-box (YB) protein-1. We tested the clinical and diagnostic value of YB-1 protein fragment p18 (YB-1/p18) detection in blood for malignant diseases.

Methods

We used a novel monoclonal anti-YB-1 antibody to detect YB-1/p18 by immunoblotting in plasma samples of healthy volunteers (n = 33), patients with non-cancerous, mostly inflammatory diseases (n = 60), hepatocellular carcinoma (HCC; n = 25) and advanced solid tumors (n = 20). YB-1/p18 was then tested in 111 patients with chronic liver diseases, alongside established tumor markers and various diagnostic measures, during evaluation for potential liver transplantation.

Results

We developed a novel immunoblot to detect the 18 kD fragment of secreted YB-1 in human plasma (YB-1/p18) that contains the cold-shock domains (CSD) 1-3 of the full-length protein. YB-1/p18 was detected in 11/25 HCC and 16/20 advanced carcinomas compared to 0/33 healthy volunteers and 10/60 patients with non-cancerous diseases. In 111 patients with chronic liver disease, YB-1/p18 was detected in 20 samples. Its occurrence was not associated with advanced Child stages of liver cirrhosis or liver function. In this cohort, YB-1/p18 was not a good marker for HCC, but proved most powerful in detecting malignancies other than HCC (60% positive) with a lower rate of false-positive results compared to established tumor markers. Alpha-fetoprotein (AFP) was most sensitive in detecting HCC, but simultaneous assessment of AFP, CA19-9 and YB-1/p18 improved overall identification of HCC patients.

Conclusions

Plasma YB-1/p18 can identify patients with malignancies, independent of acute inflammation, renal impairment or liver dysfunction. The detection of YB-1/p18 in human plasma may have potential as a tumor marker for screening of high-risk populations, e.g. before organ transplantation, and should therefore be evaluated in larger prospective studies.
Appendix
Available only for authorised users
Literature
1.
Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dorken B, Royer HD: Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med. 1997, 3 (4): 447-450. 10.1038/nm0497-447.CrossRefPubMed
2.
Bergmann S, Royer-Pokora B, Fietze E, Jurchott K, Hildebrandt B, Trost D, Leenders F, Claude JC, Theuring F, Bargou R, Dietel M, Royer HD: YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res. 2005, 65 (10): 4078-4087. 10.1158/0008-5472.CAN-04-4056.CrossRefPubMed
3.
Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jurchott K, Schmitt M, Royer HD: Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer. 2002, 97 (3): 278-282. 10.1002/ijc.1610.CrossRefPubMed
4.
Huang X, Ushijima K, Komai K, Takemoto Y, Motoshima S, Kamura T, Kohno K: Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer. Gynecol Oncol. 2004, 93 (2): 287-291. 10.1016/j.ygyno.2004.01.040.CrossRefPubMed
5.
Yahata H, Kobayashi H, Kamura T, Amada S, Hirakawa T, Kohno K, Kuwano M, Nakano H: Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol. 2002, 128 (11): 621-626. 10.1007/s00432-002-0386-6.CrossRefPubMed
6.
Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K, Yasumoto K, Sugimachi K, Kuwano M: Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res. 2001, 7 (10): 3151-3155.PubMed
7.
Oda Y, Ohishi Y, Saito T, Hinoshita E, Uchiumi T, Kinukawa N, Iwamoto Y, Kohno K, Kuwano M, Tsuneyoshi M: Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J Pathol. 2003, 199 (2): 251-258. 10.1002/path.1282.CrossRefPubMed
8.
Yasen M, Kajino K, Kano S, Tobita H, Yamamoto J, Uchiumi T, Kon S, Maeda M, Obulhasim G, Arii S, Hino O: The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma. Clin Cancer Res. 2005, 11 (20): 7354-7361. 10.1158/1078-0432.CCR-05-1027.CrossRefPubMed
9.
Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M: The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays. 2003, 25 (7): 691-698. 10.1002/bies.10300.CrossRefPubMed
10.
En-Nia A, Yilmaz E, Klinge U, Lovett DH, Stefanidis I, Mertens PR: Transcription factor YB-1 mediates DNA polymerase alpha gene expression. J Biol Chem. 2005, 280 (9): 7702-7711.CrossRefPubMed
11.
Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E, Turbin D, Berquin IM, Mertens PR, Iftner T, Gilks CB, Dunn SE: Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res. 2006, 66 (9): 4872-4879. 10.1158/0008-5472.CAN-05-3561.CrossRefPubMed
12.
Stenina OI, Shaneyfelt KM, DiCorleto PE: Thrombin induces the release of the Y-box protein dbpB from mRNA: a mechanism of transcriptional activation. Proc Natl Acad Sci USA. 2001, 98 (13): 7277-7282. 10.1073/pnas.121592298.CrossRefPubMedPubMedCentral
13.
Mertens PR, Steinmann K, Alfonso-Jaume MA, En-Nia A, Sun Y, Lovett DH: Combinatorial interactions of p53, activating protein-2, and YB-1 with a single enhancer element regulate gelatinase A expression in neoplastic cells. J Biol Chem. 2002, 277 (28): 24875-24882. 10.1074/jbc.M200445200.CrossRefPubMed
14.
Lasham A, Lindridge E, Rudert F, Onrust R, Watson J: Regulation of the human fas promoter by YB-1, Puralpha and AP-1 transcription factors. Gene. 2000, 252 (1-2): 1-13. 10.1016/S0378-1119(00)00220-1.CrossRefPubMed
15.
Berquin IM, Pang B, Dziubinski ML, Scott LM, Chen YQ, Nolan GP, Ethier SP: Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells. Oncogene. 2005, 24 (19): 3177-3186. 10.1038/sj.onc.1208504.CrossRefPubMed
16.
Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, Sorokin A, Ovchinnikov LP, Davicioni E, Triche TJ, Sorensen PH: Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell. 2009, 15 (5): 402-415. 10.1016/j.ccr.2009.03.017.CrossRefPubMed
17.
Lasham A, Moloney S, Hale T, Homer C, Zhang YF, Murison JG, Braithwaite AW, Watson J: The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor. J Biol Chem. 2003, 278 (37): 35516-35523. 10.1074/jbc.M303920200.CrossRefPubMed
18.
To K, Fotovati A, Reipas KM, Law JH, Hu K, Wang J, Astanehe A, Davies AH, Lee L, Stratford AL, Raouf A, Johnson P, Berquin IM, Royer HD, Eaves CJ, Dunn SE: Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res. 2010, 70 (7): 2840-2851. 10.1158/0008-5472.CAN-09-3155.CrossRefPubMedPubMedCentral
19.
Frye BC, Halfter S, Djudjaj S, Muehlenberg P, Weber S, Raffetseder U, En-Nia A, Knott H, Baron JM, Dooley S, Bernhagen J, Mertens PR: Y-box protein-1 is actively secreted through a non-classical pathway and acts as an extracellular mitogen. EMBO Rep. 2009, 10 (7): 783-789. 10.1038/embor.2009.81.CrossRefPubMedPubMedCentral
20.
Raffetseder U, Rauen T, Djudjaj S, Kretzler M, En-Nia A, Tacke F, Zimmermann HW, Nelson PJ, Frye BC, Floege J, Stefanidis I, Weber C, Mertens PR: Differential regulation of chemokine CCL5 expression in monocytes/macrophages and renal cells by Y-box protein-1. Kidney Int. 2009, 75 (2): 185-196. 10.1038/ki.2008.457.CrossRefPubMed
21.
Tacke F, Wustefeld T, Horn R, Luedde T, Srinivas Rao A, Manns MP, Trautwein C, Brabant G: High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol. 2005, 42 (5): 666-673. 10.1016/j.jhep.2004.12.024.CrossRefPubMed
22.
Yagmur E, Weiskirchen R, Gressner AM, Trautwein C, Tacke F: Insulin resistance in liver cirrhosis is not associated with circulating retinol-binding protein 4. Diabetes Care. 2007, 30 (5): 1168-1172. 10.2337/dc06-2323.CrossRefPubMed
23.
Dahl E, En-Nia A, Wiesmann F, Krings R, Djudjaj S, Breuer E, Fuchs T, Wild PJ, Hartmann A, Dunn SE, Mertens PR: Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer. BMC Cancer. 2009, 9: 410-10.1186/1471-2407-9-410.CrossRefPubMedPubMedCentral
24.
Shevchenko A, Wilm M, Vorm O, Mann M: Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Analytical chemistry. 1996, 68 (5): 850-858. 10.1021/ac950914h.CrossRefPubMed
25.
Tacke F, Brabant G, Kruck E, Horn R, Schoffski P, Hecker H, Manns MP, Trautwein C: Ghrelin in chronic liver disease. J Hepatol. 2003, 38 (4): 447-454. 10.1016/S0168-8278(02)00438-5.CrossRefPubMed
26.
Yagmur E, Trautwein C, Gressner AM, Tacke F: Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. Am J Gastroenterol. 2006, 101 (6): 1244-1252. 10.1111/j.1572-0241.2006.00543.x.CrossRefPubMed
27.
Marrero JA, Lok AS: Newer markers for hepatocellular carcinoma. Gastroenterology. 2004, 127 (5 Suppl 1): S113-119.CrossRefPubMed
28.
Spangenberg HC, Thimme R, Blum HE: Serum markers of hepatocellular carcinoma. Semin Liver Dis. 2006, 26 (4): 385-390. 10.1055/s-2006-951606.CrossRefPubMed
29.
Giannini E, Borro P, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Risso D, Lantieri PB, Antonucci A, Boccato M, Milone S, Testa R: Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. Int J Biol Markers. 2000, 15 (3): 226-230.PubMed
30.
Goonetilleke KS, Siriwardena AK: Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2006
31.
Collazos J, Genolla J, Ruibal A: Evaluation of the behavior of carcinoembryonic antigen in cirrhotic patients. Int J Biol Markers. 1992, 7 (4): 244-248.PubMed
32.
Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA: The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem. 1998, 35 (Pt 1): 99-103.CrossRefPubMed
33.
Tischendorf JJ, Hecker H, Kruger M, Manns MP, Meier PN: Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. Am J Gastroenterol. 2007, 102 (1): 107-114. 10.1111/j.1572-0241.2006.00872.x.CrossRefPubMed
34.
Tacke F, Fiedler K, von Depka M, Luedde T, Hecker H, Manns MP, Ganser A, Trautwein C: Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease. Liver Int. 2006, 26 (2): 173-181. 10.1111/j.1478-3231.2005.01205.x.CrossRefPubMed
35.
Duffy MJ: Role of tumor markers in patients with solid cancers: A critical review. Eur J Intern Med. 2007, 18 (3): 175-184. 10.1016/j.ejim.2006.12.001.CrossRefPubMed
36.
Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA: Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004, 350 (22): 2239-2246. 10.1056/NEJMoa031918.CrossRefPubMed
37.
Tao LY, Cai L, He XD, Liu W, Qu Q: Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Am Surg. 2010, 76 (11): 1210-1213.PubMed
38.
Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M, Day C, Trerotoli P, Giannelli G, Manas D, Reeves H: AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer. 2008, 8: 200-10.1186/1471-2407-8-200.CrossRefPubMedPubMedCentral
39.
Bachtiar I, Santoso JM, Atmanegara B, Gani RA, Hasan I, Lesmana LA, Sulaiman A, Gu J, Tai S: Combination of alpha-1-acid glycoprotein and alpha-fetoprotein as an improved diagnostic tool for hepatocellular carcinoma. Clin Chim Acta. 2009, 399 (1-2): 97-101. 10.1016/j.cca.2008.09.024.CrossRefPubMed
40.
Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, Shums Z, Aoki T, Hasegawa K, Beck Y, Sugawara Y, Kokudo N: AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol. 2010, 45 (12): 1272-1282. 10.1007/s00535-010-0278-5.CrossRefPubMed
41.
Nomura F, Koyama A, Ishijima M, Takano S, Narita M, Nakai T: Serum levels of five tumor markers for lung cancer in patients with chronic renal failure. Oncol Rep. 1998, 5 (2): 389-392.PubMed
42.
Filella X, Cases A, Molina R, Jo J, Bedini JL, Revert L, Ballesta AM: Tumor markers in patients with chronic renal failure. Int J Biol Markers. 1990, 5 (2): 85-88.PubMed
Metadata
Title
Y-box protein-1/p18 fragment identifies malignancies in patients with chronic liver disease
Authors
Frank Tacke
Nicolas Kanig
Abdelaziz En-Nia
Thilo Kaehne
Christiane S Eberhardt
Victoria Shpacovitch
Christian Trautwein
Peter R Mertens
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-185

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Research article

A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone

Research article

The prognostic effect of ethnicity for gastric and esophageal cancer: the population-based experience in British Columbia, Canada

Research article

The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro

Research article

Downregulation of TGF-beta receptor types II and III in oral squamous cell carcinoma and oral carcinoma-associated fibroblasts

Research article

The role of a new CD44st in increasing the invasion capability of the human breast cancer cell line MCF-7

Research article

Inflammatory mediators in breast cancer: Coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits